Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 5 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

33%

1 of 3 completed trials have results

Key Signals

1 recruiting1 with results

Enrollment Performance

Analytics

Phase 1
1(100.0%)
1Total
Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials
NCT05562323Recruiting

Characterization of Vaccine-induced Responses Against Monkeypox (MoVIHvax) An Observational Prospective Cohort Study

Role: collaborator

NCT05522296Completed

Break-through Infection Following Mpox vaccinatIon

Role: collaborator

NCT02616874Phase 1Completed

Study to Evaluate the Safety and Effect of HIVconsv Vaccines in Combination With Histone Deacetylase Inhibitor Romidepsin on the Viral Rebound Kinetic After Treatment Interruption in Early Treated HIV-1 Infected Individuals

Role: collaborator

NCT03835546Completed

Study to Assess the ART Impact on the Brain Outcomes. The ARBRE Study

Role: collaborator

NCT03996941Unknown

Harm Reduction Program For Informal PrEP Users In A Community-based Setting (seguiPrEP)

Role: lead

All 5 trials loaded